Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among texas medicaid recipients

Clinical Therapeutics

Volumn 30, Issue 10, 2008, Pages 1893-1907

  Cheong, Chelim ^a   Barner, Jamie C ^a   Lawson, Kenneth A ^a   Johnsrud, Michael T ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

adherence; antidiabetic medications; cost; dual therapy; fixed dose combination therapy; Texas Medicaid

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIPIZIDE; GLIPIZIDE PLUS METFORMIN; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; PATIENT COMPLIANCE; REIMBURSEMENT; RETROSPECTIVE STUDY; UNITED STATES;

COHORT STUDIES; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE CLAIM REVIEW; INSURANCE, HEALTH, REIMBURSEMENT; LOGISTIC MODELS; MALE; MEDICAID; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; TEXAS; UNITED STATES;

EID: 55949097996     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.10.003     Document Type: Article

References (40)

1. National Center for Health Statistics. Centers for Disease Control and Prevention, 2004-2006 National Health Interview Survey (NHIS) (September 29, 2008). http://www.cdc.gov/nchs/nhis.htm Accessed
2. The UK Prospective Diabetes Study Group. UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 21 (1998) 87-92
3. Turner R.C., Cull C.A., Frighi V., Holman R.R., and for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 281 (1999) 2005-2012
4. DeFronzo R.A., Goodman A.M., and for the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333 (1995) 541-549
5. Paes A.H., Bakker A., and Soe-Agnie C.J. Impact of dosage frequency on patient compliance. Diabetes Care 20 (1997) 1512-1517
6. Venturini F., Nichol M.B., Sung J.C., et al. Compliance with sulfonylureas in a health maintenance organization: A pharmacy record-based study. Ann Pharmacother 33 (1999) 281-288
7. Morningstar B.A., Sketris I.S., Kephart G.C., and Sclar D.A. Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther 27 (2002) 213-220
8. Dezii C.M., Kawabata H., and Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 95 (2002) 68-71
9. Dailey G., Kim M.S., and Lian J.F. Patient compliance and persistence with antihyperglycemic drug regimens: Evaluation of a Medicaid patient population with type 2 diabetes mellitus. Clin Ther 23 (2001) 1311-1320
10. Donnan P.T., MacDonald T.M., and Morris A.D. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: A retrospective cohort study. Diabet Med 19 (2002) 279-284
11. Melikian C., White T.J., Vanderplas A., et al. Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 24 (2002) 446-467
12. MacLaughlin E.J., Raehl C.L., Treadway A.K., et al. Assessing medication adherence in th he elderly: Which tools to use in clinical practice?. Drugs Aging 22 (2005) 231-255
13. Grant R.W., Devita N.G., Singer D.E., and Meigs J.B. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 26 (2003) 1408-1412
14. Nagasawa M., Smith M.C., and Barnes J.H. Meta-analysis of correlates of diabetes patients' compliance with prescribed medications. Diabetes Educator 16 (1989) 192-200
15. Cramer J.A. A systematic review of adherence with medications for diabetes. Diabetes Care 27 (2004) 1218-1224
16. Horne R., and Weinman J. Patients' beliefs about prescribed medicines and their role in adherence o treatment in chronic physical illness. J Psychosom Res 47 (1999) 555-567
17. McCord E.C., and Brandenburg C. Beliefs and attitudes of persons with diabetes. Fam Med 27 (1995) 267-271
18. Piette J.D., Heisler M., and Wagner T.H. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care 27 (2004) 384-391
19. Guillausseau P.J. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes: A survey in general practice. Diabetes Metab 29 (2003) 79-81
20. Schectman J.M., Nadkarni M.M., and Voss J.D. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 25 (2002) 1015-1021
21. Hepke K.L., Martus M.T., and Share D.A. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 10 (2004) 144-151
22. Sica D.A. Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs 62 (2002) 443-462
23. Blonde L., Wogen J., Kreilick C., and Seymour A.A. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 5 (2003) 424-431
24. Pan F., Chernew M.E., and Fendrick A.M. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 23 (2008) 611-614
25. Vanderpoel D.R., Hussein M.A., Watson Heidari T., and Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: A retrospective database analysis. Clin Ther 26 (2004) 2066-2075
26. Leichter S.B., and Thomas S. Combination medications in diabetes care: An opportunity that merits more attention. Clin Diabetes 21 (2003) 175-178
27. Wertheimer A.I., and Morrison A. Combination drugs: Innovation in pharmacotherapy. Pharm Ther 27 (2002) 44-49
28. Texas Health and Human Services Commission. Texas Medicaid in perspective. Fifth edition-June 2004 (The "Pink Book") (July 23, 2005). http://www.hhsc.state.tx.us/medicaid/reports/PB5/PinkBookTOC.html Accessed
29. Cramer J.A., Roy A., Burrell A., et al. Medication compliance and persistence: Terminology and definitions. Value Health 11 (2008) 44-47
30. Rudd P., Ahmed S., Zachary V., et al. Antihypertensive drug trials, contributions from medication monitors. In: Cramer J.A., and Spilker B. (Eds). Patient Compliance in Medical Practice and Clinical Trials (1991), Raven Press, New York, NY 283-299
31. In: Tabachnick B.G., and Fidell L.S. (Eds). Using Multivariate Statistics. 3rd ed (1996), HarperCollins College Publishers, New York, NY
32. In: Polit D.F., and Hungler B.P. (Eds). Nursing Research: Principles and Methods. 6th ed (1999), Lippincott, Philadelphia, Pa
33. Sharkness C.M., and Snow D.A. The patient's view of hypertension and compliance. Am J Prev Med 8 (1992) 141-146
34. Shalansky S.J., and Levy A.R. Effect of number of medications on cardiovascular therapy adherence. Ann Pharmacother 36 (2002) 1532-1539
35. Burge S., White D., Bajorek E., et al. Correlates of medication knowledge and adherence: Findings from the residency research network of South Texas. Fam Med 37 (2005) 712-718
36. Von Korff M., Wagner E.H., and Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 45 (1992) 197-203
37. Clark D.O., Von Korff M., Saunders K., et al. A chronic disease score with empirically derived weights. Med Care 33 (1995) 783-795
38. Feinberg D.B. Pharmacy Law: Textbook & Review (2007), McGraw-Hill, New York, NY
39. Texas Health and Human Services Commission. Oral antidiabetic agents (July 23, 2005). http://www.hhsc.state.tx.us/hcf/vdp/criteria/antidiab.html Accessed
40. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther 20 (1998) 764-771